Safety of high concentration intravenous nicardipine infusion in adult patients

Clinical question

What safety observations were reported when an academic center used a 0.5 mg/mL intravenous nicardipine infusion in adults, and what can those observations reasonably support in practice?

Bottom line

In a single-center retrospective cohort, 51 adults received a 0.5 mg/mL nicardipine infusion and no concentration-related adverse drug events were documented. Most infusions used central access; nine used peripheral access and five midline access. This is an initial safety observation, not proof of a zero event rate, routine peripheral-infusion safety, or superiority over lower-concentration or alternative antihypertensive strategies.

PICO-style framing

Population. Adults at a 576-bed academic center who received high-concentration intravenous nicardipine from January 2014 through September 2024. Infusions shorter than two hours were excluded.

Exposure. Locally compounded nicardipine 0.5 mg/mL (50 mg in 100 mL of 0.9% sodium chloride).

Comparator. This was a single-arm retrospective safety study; there was no concurrent lower-concentration, alternate-agent, or access-type comparator.

Outcome. Documented adverse drug events judged related to the high concentration. Access type and infusion characteristics were also described.

What did the study find?

Eighty-one patients were assessed and 51 met inclusion criteria. Median age was 55 years (IQR 41-64.5), and 70.6% were male. The investigators found no documented concentration-related adverse drug events. Most infusions were through central access; nine used peripheral access and five used midline access.

The result is clinically relevant because a more concentrated preparation can reduce infusion volume. It does not, however, compare this preparation with a lower concentration or clevidipine, measure a precise comparative event rate, or establish that peripheral use is safe as routine practice. Absence of a recorded event among 51 selected records is reassuring but imprecise.

Appraisal

This was a retrospective, single-center, single-arm chart review. It can describe what happened under one institution’s compounding, monitoring, access, and documentation practices. It cannot establish causation or comparative safety. Rare events may not appear in a sample of this size, and documented adverse events depend on recognition and chart capture.

The study excluded infusions under two hours, so its findings do not automatically extend to shorter courses. The access distribution also matters: the experience was predominantly central rather than peripheral. The paper’s local product was compounded with a defined diluent and container, and the institutional standards described central access preference. A learner should not convert that local process into a general compounding instruction without pharmacy, vascular-access, and institutional governance review.

The present cohort cannot establish peripheral-access safety because only nine peripheral infusions were observed and there was no controlled comparison.

Practical interpretation

The study supports a cautious statement: at this center, no concentration-related adverse drug events were documented among 51 included adults receiving a 0.5 mg/mL infusion. If a concentrated strategy is contemplated locally, decisions should be made through institutional medication-use, pharmacy-compounding, nursing, and vascular-access standards. Confirm the approved preparation, diluent, container, line type, monitoring, and escalation process before administration.

Do not teach that the study proves routine peripheral 0.5 mg/mL nicardipine is safe. Do not claim a comparative advantage over other nicardipine concentrations or clevidipine. Operational implementation remains subject to local governance.

Limits to carry forward

• Single-center, retrospective, single-arm design.
• Only 51 included patients; rare harms and differences between access types remain uncertain.
• Predominantly central access limits peripheral-access inference.
• No comparator: no proof of comparative safety, effectiveness, or superiority.
• Local compounding and governance cannot be generalized as a universal protocol.

Learning pearls

1. “No documented event” is an observation, not a proof of zero risk.
2. Separate preparation concentration from line-access safety and from antihypertensive effectiveness.
3. Read the access distribution before making a peripheral-line claim.
4. Use institutional medication and vascular-access governance for implementation decisions.

ACPE UAN: 0683-0000-26-036-H01-P

---

Study source: DOI:10.67122/001c.146665